Last reviewed · How we verify
14-day Cerebrolysin treatment
14-day Cerebrolysin treatment is a Small molecule drug developed by Cardinal Stefan Wyszynski University. It is currently FDA-approved.
14-day Cerebrolysin treatment is a marketed drug developed by Cardinal Stefan Wyszynski University, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that differentiates it from other treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | 14-day Cerebrolysin treatment |
|---|---|
| Sponsor | Cardinal Stefan Wyszynski University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU (PHASE3)
- Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial (PHASE4)
- Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion (EARLY_PHASE1)
- Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke (PHASE4)
- Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14-day Cerebrolysin treatment CI brief — competitive landscape report
- 14-day Cerebrolysin treatment updates RSS · CI watch RSS
- Cardinal Stefan Wyszynski University portfolio CI